TrialInvestigational new drugs2014

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

A Ruzsa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.